You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Highly selective CB2 receptor agonist (Ki values are 11.8 and 4888 nM for CB2 and CB1 receptors respectively). Potently inhibits forskolin-stimulated cAMP production via CB2 receptors expressed in CHO cells (EC50 = 3.1 nM).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Ross et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br.J.Pharmacol. 126 665 PMID: 10188977
Huffman (2005) CB2 receptor ligands. Mini Rev.Med.Chem. 5 641 PMID: 16026310
Huffman (2000) The search for selective ligands for the CB2 receptor. Curr.Pharmaceut.Des. 6 1323
View Related Products by Product Action
Keywords: L-759,656, L-759,656 supplier, selective, CB2, agonists, cannabinoids, Receptors, cb2r, L759656, 2434, Tocris Bioscience
Citations for L-759,656
Citations are publications that use Tocris products.
Currently there are no citations for L-759,656.
Reviews for L-759,656
There are currently no reviews for this product. Be the first to review L-759,656 and earn rewards!
Have you used L-759,656?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.